Treating psoriatic arthritis: how effective are TNF antagonists?
Open Access
- 1 January 2004
- journal article
- review article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 6 (2) , S31-S35
- https://doi.org/10.1186/ar1016
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)Arthritis & Rheumatism, 2005
- Alefacept treatment in psoriatic arthritis: Reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritisArthritis & Rheumatism, 2002
- Open‐label study of infliximab treatment for psoriatic arthritis: Clinical and magnetic resonance imaging measurements of reduction of inflammationArthritis Care & Research, 2002
- Randomized double‐blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondylarthropathyArthritis & Rheumatism, 2002
- Infliximab and Methotrexate in the Treatment of Rheumatoid ArthritisNew England Journal of Medicine, 2000
- A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid ArthritisNew England Journal of Medicine, 2000
- PSORIATIC ARTHRITISRheumatic Disease Clinics of North America, 1998
- Anti-inflammatory efficacy of low-dose cyclosporin A in psoriatic arthritis. A prospective multicentre studyBritish Journal of Dermatology, 1996
- The role of hla antigens as indicators of disease progression in psoriatic arthritisArthritis & Rheumatism, 1995
- PSORIATIC ARTHRITIS: OUTCOME OF DISEASE SUBSETS AND RELATIONSHIP OF JOINT DISEASE TO NAIL AND SKIN DISEASERheumatology, 1994